Tag Archives: age-related macular degeneration

November, 2018

12 November
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet Age-Related Macular Degeneration

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (NASDAQ:OPHT) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD …
Share

17 August
FDA Approves Regeneron’s Eylea Injection sBLA in Wet Age-Related Macular Degeneration

TARRYTOWN, N.Y., Aug. 17, 2018 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). The sBLA was based on second-year …
Share

19 July
Allergan and Molecular Partners Announce Positive Results from Two Phase 3 Trials of Abicipar Pegol for Age-Related Macular Degeneration

DUBLIN, July 19, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced the release of two positive clinical trials, SEQUOIA and CEDAR for abicipar, demonstrating that both the 8-week and 12-week …
Share

25 August
Apellis’ APL-2 Meets Primary Endpoint in Phase 2 Study in Patients with Geographic Atrophy Associated with AMD

LOUISVILLE, Ky.–(BUSINESS WIRE)–Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that its complement C3 inhibitor, APL-2, met its primary endpoint in a Phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA) associated with age-related …
Share

20 June
Novartis’ Wet AMD Drug Meets Primary and Key Secondary Endpoints in Two Late-Stage Studies

Basel, June 20, 2017 – Novartis, the global leader in Ophthalmology, today reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two Phase III studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These pivotal studies enrolled more than 1,800 …
Share

10 February
International Team of Researchers Develop New Model for Earlier Treatments for AMD

An international team of researchers from Queen’s University Belfast, University College London and the University of Alabama at Birmingham, USA have developed a cell culture model that could help to develop earlier treatment strategies for age-related macular degeneration (AMD). AMD, which is the third most prevalent cause of vision loss …
Share

17 October
FDA Approves Genentech’s Lucentis Prefilled Syringe

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, …
Share
13 October
Ocular Therapeutix and Regeneron Collaborate for Development of New Eylea Formulation

BEDFORD, Mass–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Ocular and Regeneron will …
Share

8 August
Pfenex Regains Full Rights to its Biosimilar Candidate and Announces Phase I/II Results

SAN DIEGO, Aug. 8, 2016 /PRNewswire/ — Pfenex Inc. (NYSE MKT: PFNX) announced today that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis®, following our partner’s strategic review of the current therapeutic focus of its biosimilar pipeline. “With Pfenex regaining the rights to PF582 …
Share

25 March
Bayer and Regeneron Partner to Develop Novel Combination Therapy for Eye Diseases

TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating …
Share